Greenland Mines Ltd. Common Stock (NASDAQ:GRML – Get Free Report) Director Jason David Sawyer acquired 240,000 shares of the company’s stock in a transaction that occurred on Wednesday, July 22nd. The shares were acquired at an average price of $0.23 per share, with a total value of $55,200.00. Following the acquisition, the director owned 240,000 shares in the company, valued at $55,200. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Greenland Mines Ltd. Common Stock Stock Performance
GRML stock traded up $0.00 during midday trading on Tuesday, reaching $0.19. The company’s stock had a trading volume of 1,780,737 shares, compared to its average volume of 4,296,581. Greenland Mines Ltd. Common Stock has a 1 year low of $0.16 and a 1 year high of $1.12. The firm has a market capitalization of $26.60 million, a price-to-earnings ratio of -0.60 and a beta of 7.05. The stock has a fifty day simple moving average of $0.28 and a two-hundred day simple moving average of $0.37.
Greenland Mines Ltd. Common Stock (NASDAQ:GRML – Get Free Report) last posted its quarterly earnings results on Wednesday, May 20th. The company reported ($0.15) EPS for the quarter.
Institutional Trading of Greenland Mines Ltd. Common Stock
Analysts Set New Price Targets
Several brokerages have issued reports on GRML. Wall Street Zen upgraded shares of Greenland Mines Ltd. Common Stock to a “sell” rating in a report on Saturday, May 2nd. Weiss Ratings raised shares of Greenland Mines Ltd. Common Stock from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, July 15th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Greenland Mines Ltd. Common Stock has a consensus rating of “Sell”.
View Our Latest Research Report on Greenland Mines Ltd. Common Stock
About Greenland Mines Ltd. Common Stock
Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases – cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.
Further Reading
- Five stocks we like better than Greenland Mines Ltd. Common Stock
- Western Digital’s Earnings Will Test Whether Its AI Rally Has More Room
- Is the Market Mispricing ServiceNow’s AI Future?
- Nano Nuclear’s Air Force Contract Puts Its Short-Squeeze Setup in Focus
- Amkor Sells Off After Earnings—Why Weak Guidance Isn’t the Real Story
Receive News & Ratings for Greenland Mines Ltd. Common Stock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Greenland Mines Ltd. Common Stock and related companies with MarketBeat.com's FREE daily email newsletter.
